Acer Therapeutics Announces Initiation of Two Investigator-Sponsored Trials of ACER-801 (Osanetant) in Men with Adenocarcinoma of the Prostate

Acer Therapeutics Inc. announced the initiation of two Phase II, single-arm investigator-sponsored trials evaluating ACER-801 in men with adenocarcinoma of the prostate.